Long-term efficacy of sulfonylureas: a United Kingdom Prospective Diabetes Study perspective.
about
The management of type 2 diabetic patients with hypoglycaemic agentsβ-Cell failure in type 2 diabetes.Incidence of bladder cancer in patients with type 2 diabetes treated with metformin or sulfonylureas.Tesaglitazar, as add-on therapy to sulphonylurea, dose-dependently improves glucose and lipid abnormalities in patients with type 2 diabetes.Lean diabetes mellitus: An emerging entity in the era of obesity.Antidiabetic Effects of Add-On Gynostemma pentaphyllum Extract Therapy with Sulfonylureas in Type 2 Diabetic Patients.Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes.The effect of sulphonylureas on the microvascular and macrovascular complications of diabetes.Change in cardiovascular risk factors following early diagnosis of type 2 diabetes: a cohort analysis of a cluster-randomised trial.The design of the liraglutide clinical trial programme.Noninsulin glucose-lowering agents for the treatment of patients on dialysis.Optimal utilisation of sulphonylureas in resource-constrained settingsCombination of mangiferin and dipeptidyl peptidase-4 inhibitor sitagliptin improves impaired glucose tolerance in streptozotocin-diabetic rats.The beneficial effect of metformin on β-cell function in non-obese Chinese subjects with newly diagnosed type 2 diabetes.Prevalence and characteristics of non-obese diabetes in Japanese men and women: the Yuport Medical Checkup Center Study.Non-obese patients with type 2 diabetes and prediabetic subjects: distinct phenotypes requiring special diabetes treatment and (or) prevention?Randomized trial assessing the safety and efficacy of sitagliptin in Chinese patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea alone or combined with metformin.Sulfonylureas or dipeptidyl peptidase (DPP-4) inhibitors in the management of type 2 diabetes: debate is not yet closed.Sitagliptin add-on to low dosage sulphonylureas: efficacy and safety of combination therapy on glycaemic control and insulin secretion capacity in type 2 diabetes
P2860
Q30417363-6C1ABF4E-BFDF-41AD-825D-3DF9F30C8B0EQ33588325-91B015B6-9EC4-4A3D-AAF3-D9664663D953Q33793812-B5FD5410-6151-4563-B8D7-FF5B07AB759CQ34695851-31D66B2E-1B28-4AE2-AEEB-E5F58BC4990FQ35613913-C220F8A7-FC92-476D-A368-4A4B2499246AQ36357709-1D158BF4-0950-40B5-A717-7DC3C718805CQ36764031-ADCD73EC-6269-4C2C-B044-6C732B641485Q37089814-DB5E9D4E-5A12-4A65-B5D5-DDEFFB6E3CD0Q37660835-432724DB-B87A-4A2A-900B-E5393E6621BFQ37992253-104A7415-5AD9-422A-94A1-653790AEC6C4Q38077451-9E854D7F-1F0E-4812-B6FF-8AC17BB0BF05Q38213126-5E85D7F8-82C2-48F3-B814-154B0FC8F6FAQ42716091-1DDB6F01-D29C-4260-80B3-54988F916A12Q44685753-FC08ED2E-9C56-4FC9-9D1D-0F5394944AAEQ44995947-074A6C09-F4F9-41EC-85BC-06E8959470CAQ46865865-96DB3ABB-C857-4271-A4D1-C42BCFD4DD58Q51280718-672985F8-BCA4-4491-A1C7-8177A6C8141DQ54358422-32796EEB-CD5E-4564-B960-32E0EFD61296Q57591354-F5A89A14-3EF0-4BD2-A5B3-C7A71047C944
P2860
Long-term efficacy of sulfonylureas: a United Kingdom Prospective Diabetes Study perspective.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Long-term efficacy of sulfonyl ...... ve Diabetes Study perspective.
@ast
Long-term efficacy of sulfonyl ...... ve Diabetes Study perspective.
@en
type
label
Long-term efficacy of sulfonyl ...... ve Diabetes Study perspective.
@ast
Long-term efficacy of sulfonyl ...... ve Diabetes Study perspective.
@en
prefLabel
Long-term efficacy of sulfonyl ...... ve Diabetes Study perspective.
@ast
Long-term efficacy of sulfonyl ...... ve Diabetes Study perspective.
@en
P1433
P1476
Long-term efficacy of sulfonyl ...... ive Diabetes Study perspective
@en
P2093
Rury R Holman
P356
10.1016/J.METABOL.2006.02.006
P433
P50
P577
2006-05-01T00:00:00Z